Venrock Healthcare Capital Par Purchases 100,000 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par bought 100,000 shares of the company's stock in a transaction dated Wednesday, February 12th. The stock was bought at an average cost of $9.23 per share, with a total value of $923,000.00. Following the transaction, the insider now directly owns 5,217,285 shares in the company, valued at approximately $48,155,540.55. The trade was a 1.95 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 10th, Venrock Healthcare Capital Par bought 4,137 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average cost of $9.14 per share, for a total transaction of $37,812.18.
• On Friday, February 7th, Venrock Healthcare Capital Par purchased 73,649 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $9.29 per share, with a total value of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average price of $9.22 per share, for a total transaction of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average cost of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Price Performance

KALV stock traded down $0.00 on Tuesday, reaching $9.76. The company's stock had a trading volume of 283,338 shares, compared to its average volume of 297,643. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $15.50. The company has a market capitalization of $482.19 million, a P/E ratio of -2.68 and a beta of 0.85. The firm has a fifty day moving average of $8.77 and a two-hundred day moving average of $10.43.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.01. As a group, equities analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of KALV. Aquatic Capital Management LLC acquired a new stake in shares of KalVista Pharmaceuticals in the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC raised its holdings in KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 5,502 shares in the last quarter. Legal & General Group Plc lifted its position in KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after purchasing an additional 1,494 shares during the period. Martin Worley Group bought a new position in KalVista Pharmaceuticals during the 4th quarter valued at $86,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after purchasing an additional 2,043 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. JMP Securities started coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an "outperform" rating and a $19.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).